Lacosamide Zentiva

Lacosamide, the active ingredient in Lacosamide Zentiva, is a sodium channel blocker presented as an oral tablet for oral use. It is employed to treat partial‑onset seizures in patients with epilepsy and may be used as adjunct therapy when seizures are not adequately controlled by other antiepileptic agents.

GNH USA supplies Lacosamide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures product quality through stringent quality‑assurance processes and provides regulatory support for global distribution.

Lacosamide is indicated for seizure disorders that involve abnormal neuronal firing in the central nervous system.

- Partial-onset seizures: reduces seizure frequency and severity in patients with focal epilepsy. - Adjunct therapy for refractory epilepsy: used alongside other antiepileptic drugs when monotherapy is insufficient. - Epilepsy (focal onset): helps achieve better seizure control in individuals diagnosed with focal onset epilepsy.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of lightheadedness or imbalance. - Nausea: feeling of stomach upset or urge to vomit. - Headache: mild to moderate cranial pain. - Fatigue: unusual tiredness or lack of energy. - Blurred vision: temporary visual disturbances. - Diplopia: double vision episodes.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Cardiac arrhythmia: alterations in heart rhythm, including PR‑interval prolongation. - Suicidal ideation: thoughts of self‑harm requiring immediate evaluation. - Severe hypersensitivity: rash, fever, and organ involvement. - Rhabdomyolysis: muscle breakdown leading to elevated creatine kinase. - Anaphylaxis: acute, life‑threatening allergic reaction.

When prescribing Lacosamide, clinicians should consider several precautionary measures to ensure patient safety. - Renal impairment: assess kidney function and adjust therapy if necessary. - Cardiac monitoring: evaluate baseline ECG as Lacosamide can prolong PR interval. - Pregnancy: safety data are limited; weigh potential benefits against risks. - Concomitant antiepileptics: review for possible additive CNS effects. - Discontinuation: avoid abrupt cessation to prevent seizure worsening. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Lacosamide can interact with other medicines, influencing its plasma levels or cardiac effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase Lacosamide concentrations, raising toxicity risk. - Other sodium‑channel blockers: combined use can enhance cardiac conduction abnormalities. - Drugs that prolong PR interval (e.g., beta‑blockers): may lead to significant heart‑rate slowing.

Moderate Interactions (Monitor Closely): - Carbamazepine: may reduce Lacosamide levels, decreasing efficacy. - Phenytoin: can lower Lacosamide plasma concentrations. - Alcohol: may intensify central nervous system depression. - Anticoagulants: monitor for altered bleeding risk when used together.